Drug Profile
PBI 4425
Alternative Names: PBI-4425Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Liminal BioSciences
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action FFAR1 protein stimulants; GPR84 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute lung injury; Pulmonary fibrosis
- No development reported Diabetic nephropathies; Hepatic fibrosis; Scleroderma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Diabetic-nephropathies in Canada (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Canada (PO)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Scleroderma in Canada (PO)